|
[1]
|
Guilbert, J.J. (2003) The World Health Report 2002—Reducing Risks, Promoting Healthy Life. Education for Health (Abingdon), 16, 230. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Aggarwal, J., Reddy, S. and Nagtilak, S. (2016) Non-HDL-C: An Alternate to LDL-C for the Diagnosis of Cardiovascular Disease. IOSR Journal of Dental and Medical Sciences, 15, 1-4.
|
|
[3]
|
Teramoto, T., Sasaki, J., Ishibashi, S., et al. (2013) Comprehensive Risk Management for the Prevention of Cardiovascular Disease: Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan—2012. Journal of Atherosclerosis and Thrombosis, 20, 603-615. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Sniderman, A.D., Williams, K., Contois, J.H., et al. (2011) A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk. Circulation: Cardiovascular Quality and Outcomes, 4, 337-345. [Google Scholar] [CrossRef]
|
|
[5]
|
Nordestgaard, B.G. and Langsted, A. (2016) Lipo-protein(a) as a Cause of Cardiovascular Disease: Insights from Epidemiology, Genetics, and Biology. Journal of Lipid Research, 57, 1953-1975. [Google Scholar] [CrossRef]
|
|
[6]
|
Seki, R., Inoue, K., Yamamoto, S., et al. (2017) Non-HDL Cholesterol Is Better than Friedewald-Estimated LDL Cholesterol to Associate with Cardiometabolic Markers. Journal of BioMedical Research and Clinical Practice, 2, 1-6. [Google Scholar] [CrossRef]
|
|
[7]
|
Grundy, S.M., Stone, N.J., Bailey, A.L., et al. (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/ APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139, e1082-e1143. [Google Scholar] [CrossRef]
|
|
[8]
|
Arsenault, B.J. and Kamstrup, P.R. (2022) Lipoprotein (a) and Cardiovascular and Valvular Diseases: A Genetic Epidemiological Perspective. Atherosclerosis, 349, 7-16. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Utermann, G. (2006) Lipoprotein(a). In: Valle, D.L., Antonarakis, S., Ballabio, A., et al., Eds., The Online Metabolic and Molecular Bases of Inherited Disease (2001 Ed.), McGraw-Hill, New York.
|
|
[10]
|
Langsted, A., Nordestgaard, B.G. and Kamstrup, P.R. (2019) Elevated Lipoprotein(a) and Risk of Ischemic Stroke. Journal of the American College of Cardiology, 74, 54-66. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Zheng, K.H., Tsimikas, S., Pawade, T., et al. (2019) Lipoprotein (a) and Oxidized Phospholipids Promote Valve Calcification in Patients with Aortic Stenosis. Journal of the American Col-lege of Cardiology, 73, 2150-2162. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Langsted, A., Kamstrup, P.R. and Nordestgaard, B.G. (2019) High Lipoprotein(a) and High Risk of Mortality. European Heart Journal, 40, 2760-2770. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Burgess, S., Ference, B.A., Staley, J.R., et al. (2018) Association of LPA Variants with Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. JAMA Cardiology, 3, 619-627. [Google Scholar] [CrossRef] [PubMed]
|